COMP <GO>
SYRE vs MRK // FORWARD P/E MULTIPLE
Spyre Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: SYRE 4
— MRK 10
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $96.56 (-2.43%) • MKT CAP: $10.33B
forward-pe
22.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYRE VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYRE | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 74.80% | -30.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.00% | 20.70% | -40.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.64% | 3.42% | -5.06 | MRK | /fcf-yield <GO> |
| Operating Margin | 16.50% | 34.30% | -17.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 28.10% | -15.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 1.30% | +16.30 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | SYRE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.1 | 56.9 | +2.20 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.92 | -0.03 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 22.0x | 18.4x | +3.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.33B | $361.02B | -$350.69B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYRE REV | MRK REV | SYRE GROSS % | MRK GROSS % | SYRE FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | -$169.3M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | -$157.4M | $18.10B |
| FY 2023 | $886.0K | $60.12B | 44.0% | 44.0% | -$99.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYRE // BETA 0.89
MRK // BETA 0.92